Q-omics provides the consensus-scored ANKRD50 profile across patient tissues and cancer cell-line models. ANKRD50 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD50 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ANKRD50 RNA expression shows 20,431 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ANKRD50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD50 survival associations across molecular data types. ANKRD50 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD50 RNA expression–survival associations across cancer types. High ANKRD50 expression shows unfavorable associations in MESO, PAAD, STAD and UVM, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD50 RNA expression.
This table summarizes ANKRD50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD50 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BRCA, CHOL and STAD. The HNSC box plot shows higher ANKRD50 RNA expression in tumor versus normal tissue (log2 FC = +1.564, t-test p < 0.001).
This table shows molecular features associated with ANKRD50 in patient tissues and cancer cell lines. In patient samples, ANKRD50 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
